Press Releases July 15, 2026 08:05 AM

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

BillionToOne to announce Q2 2026 earnings on August 5, 2026 with a scheduled earnings call

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
BLLN

BillionToOne, a molecular diagnostics company specializing in accurate DNA molecule counting, plans to release its financial results for Q2 2026 after market close on August 5, 2026. The company will host a conference call and webcast to discuss the results the same day.

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
BLLN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BillionToOne is reporting its Q2 2026 financial results on August 5, 2026 after market close.
  • The company specializes in molecular diagnostics using its patented Quantitative Counting Templates (QCT) technology that counts DNA molecules at the single-molecule level.
  • A live webcast and analyst conference call are planned to discuss the results and company updates.

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested listeners will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

Investor Contact
[email protected]

Media Contact
[email protected]


Risks

  • The article does not disclose financial performance details, creating uncertainty around the upcoming results which could impact the stock price.
  • The molecular diagnostics industry is competitive and dependent on technological innovation, which may pose execution risks for BillionToOne.
  • Market reaction can be influenced by how results compare to analyst expectations and broader healthcare sector trends.

More from Press Releases

CNH Names Paul Dick, President, North America Nov 20, 2026 Harmony Biosciences to Participate in Upcoming Investor Conferences Nov 19, 2026 Pure Cycle Announces Record Financial Results For the Year Ended August 31, 2026 Nov 18, 2026 Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026